Literature DB >> 26181178

Effect of 5α-Reductase Inhibitor Use on Mortality From Prostate Cancer.

William D Figg1, Ian M Thompson2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26181178      PMCID： PMC6360025          DOI： 10.1001/jamaoncol.2015.0408

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  10 in total

1.  Effect of dutasteride on the risk of prostate cancer.

Authors:  Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster
Journal:  N Engl J Med       Date:  2010-04-01       Impact factor: 91.245

2.  The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.

Authors:  Marc R Theoret; Yang-Min Ning; Jenny J Zhang; Robert Justice; Patricia Keegan; Richard Pazdur
Journal:  N Engl J Med       Date:  2011-06-15       Impact factor: 91.245

3.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

4.  Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.

Authors:  Ian M Thompson; Chen Chi; Donna Pauler Ankerst; Phyllis J Goodman; Catherine M Tangen; Scott M Lippman; M Scott Lucia; Howard L Parnes; Charles A Coltman
Journal:  J Natl Cancer Inst       Date:  2006-08-16       Impact factor: 13.506

5.  5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.

Authors:  Laurent Azoulay; Maria Eberg; Serge Benayoun; Michael Pollak
Journal:  JAMA Oncol       Date:  2015-06       Impact factor: 31.777

Review 6.  Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention.

Authors:  Edith Canby-Hagino; Javier Hernandez; Timothy C Brand; Ian Thompson
Journal:  Eur Urol       Date:  2006-09-15       Impact factor: 20.096

7.  Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.

Authors:  Ian M Thompson; Catherine M Tangen; Phyllis J Goodman; M Scott Lucia; Howard L Parnes; Scott M Lippman; Charles A Coltman
Journal:  J Urol       Date:  2007-05       Impact factor: 7.450

8.  The influence of finasteride on the development of prostate cancer.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

9.  Long-term survival of participants in the prostate cancer prevention trial.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; Howard L Parnes; Lori M Minasian; Paul A Godley; M Scott Lucia; Leslie G Ford
Journal:  N Engl J Med       Date:  2013-08-15       Impact factor: 91.245

10.  Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

Authors:  M Scott Lucia; Jonathan I Epstein; Phyllis J Goodman; Amy K Darke; Victor E Reuter; Francisco Civantos; Catherine M Tangen; Howard L Parnes; Scott M Lippman; Francisco G La Rosa; Michael W Kattan; E David Crawford; Leslie G Ford; Charles A Coltman; Ian M Thompson
Journal:  J Natl Cancer Inst       Date:  2007-09-11       Impact factor: 13.506
  10 in total
  3 in total

1.  5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia.

Authors:  Lauren P Wallner; Julia R DiBello; Bonnie H Li; Stephen K Van Den Eeden; Sheila Weinmann; Debra P Ritzwoller; Jill E Abell; Ralph D'Agostino; Ronald K Loo; David S Aaronson; Kathryn Richert-Boe; Ralph I Horwitz; Steven J Jacobsen
Journal:  Mayo Clin Proc       Date:  2016-10-27       Impact factor: 7.616

2.  The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality.

Authors:  Lauren P Wallner; Julia R DiBello; Bonnie H Li; Stephen K Van Den Eeden; Sheila Weinmann; Debra P Ritzwoller; Jill E Abell; Ralph D'Agostino; Ronald K Loo; David S Aaronson; Ralph I Horwitz; Steven J Jacobsen
Journal:  Urology       Date:  2018-06-12       Impact factor: 2.649

Review 3.  Oxidative stress in prostate hyperplasia and carcinogenesis.

Authors:  Udensi K Udensi; Paul B Tchounwou
Journal:  J Exp Clin Cancer Res       Date:  2016-09-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.